Option chain shows key data for X4 Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for X4 Pharmaceuticals.

X4 Pharmaceuticals (NASDAQ:XFOR) Stock, Option Chain

X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

biotech shutter

Biotech

Equities

News

Previews

Markets

Trading Ideas

ARWR

DSKYF

NTLA

REGN

VRNA

XFOR

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Lab.julia koblitz

Health Care

General

FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil &amp; lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.

FDA Approves X4 Pharmaceuticals&#39; Mavorixafor As First Therapy For Rare Immunodeficiency Disorder

Penny Stocks

Small Cap

Intraday Update

Movers

AAGR

APLS

BLUE

BMEA

BPMC

BTBT

CLSK

COMM

CYTO

DISH

DOGZ

EFTR

HIVE

IONM

IPDN

ISUN

JTAI

KROS

KTTA

MARA

MINM

Morgan Stanley Capital Protected Notes for S&P 500 Index

NXTP

ONTX

RIOT

SHAK

TRKA

VAPO

VERU

WULF

ZLAB

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting &amp; Exposition.

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc Warrants (12/04/2024)

Macro Economic Events

Econ #s

Economics

U.K. Core Retail Sales (YoY) For October 2.0% Vs. 3.3% Est.; 3.2% (Revised) Prior

U.K. Core Retail Sales (MoM) For October -0.9% Vs. -0.3% Est.; 0.1% (Revised) Prior

The Securities and Exchange Commission&#8217;s (SEC) <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42098407/donald-trump-reportedly-eyeing-the-first-crypto-focused-role-in-the-white-house">lawsuits against cryptocurrency companies</a> will likely reach settlements once Chair Gary Gensler steps down in January 2025, according to crypto asset manager Pantera&#8216;s chief legal officer Katrina Paglia.
What Happened: Speaking at the North American Blockchain Summit in Dallas on Thursday, Paglia <a href="https://cointelegraph.com/news/sec-lawsuits-quietly-go-away-after-gensler-steps-down-pantera-clo">said</a>, according to Cointelegraph that while the SEC won&#8217;t completely withdraw its claims, many cases will &#8220;quietly go away&#8221; with defendants paying settlements under &#8220;neither admit nor deny&#8221; terms.
&#8220;The regulator will get to make some level of a statement and get something for the value of time and energy spent,&#8221; Paglia said, noting this would be &#8220;very beneficial&#8221; for resolving the extensive litigation.
The comments come as President-elect Donald Trump&#8216;s transition team actively shapes what appears to be a dramatically different approach to crypto regulation. 
See Also: <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">Bitcoin Analyst Warns Of &#8216;4-6 Flash Crashes&#8217; Before Year-End As It Inches Closer To $100K: That&#8217;s The Moment Altcoins &#8216;Shoot Off&#8217;</a>
Why It Matters: The incoming administration is reportedly vetting candidates for the first-ever White House <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42098407/donald-trump-reportedly-eyeing-the-first-crypto-focused-role-in-the-white-house">cryptocurrency policy role</a> while major industry players like Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) CEO Brian Armstrong engage in <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42114875/coinbase-ceo-brian-armstrong-stands-out-as-candidate-for-donald-trumps-reported-crypto-czar-position-cardano-co-founder-says">high-level discussions</a>.
Industry experts see the potential for <a href="https://www.benzinga.com/24/11/42069770/us-congress-could-set-the-stage-for-broader-crypto-adoption-says-digital-asset-leader">significant policy shifts</a>, with Hunting Hill Global Capital&#8216;s CIO Adam Guren emphasizing the need for &#8220;thoughtful policy&#8221; and clear definitions for digital assets. &#8220;Well-defined classifications would encourage engagement from both individual and institutional investors,&#8221; Guren noted.
The market has responded positively to these developments, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">approaching $100,000</a> amid reports that companies including Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Kraken, and Circle (CRYPTO: USD) are seeking representation on <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122348/trumps-planned-crypto-council-may-oversee-bitcoin-reserve-report">Trump&#8217;s promised crypto advisory council</a>.
The SEC under Gensler&#8217;s leadership has pursued actions against numerous high-profile crypto companies, including Ripple, Binance (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), Kraken, and others, in what many in the industry have characterized as an aggressive regulatory approach.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">Bitcoin&#8217;s Path To $100K &#8216;Inevitable&#8217; But Crypto Community Is &#8216;Leveraged To The Gills,&#8217; Warns Galaxy&#8217;s Mike Novogratz, Predicts Correction To $80K Ahead</a></li>
</ul>
SEC Gary Gensler. Photo by Third Way Think Tank on Flickr
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$XRP

COIN

With Gary Gensler Preparing To Quit In 2025, SEC's Crypto Cases Likely To 'Quietly Go Away' Amid Trump's Pro-Bitcoin Stance, Says Pantera Capital's Katrina Paglia

The Company intends to use net proceeds from the offering for general corporate purposes, which may include new debt and equity investment opportunities and the repayment of a portion of its outstanding indebtedness.

Reported Earlier, SL Green Realty Prices 5,063,291 Common Shares At $79/Share

The billionaire Republican megadonor and Citadel CEO Ken Griffin has expressed openness to selling a minority stake in the $65 billion hedge fund he established in 1990.
What Happened: Griffin has previously sold stakes in his ventures. Two years ago, Sequoia Capital acquired a stake in Citadel Securities for $1.15 billion, valuing the market maker at $22 billion. Recently, Citadel Securities received a $5 billion investment offer from a private equity firm, which Griffin mentioned would help the company remain private longer.
In an <a href="https://www.bloomberg.com/news/articles/2024-11-21/ken-griffin-says-he-s-open-to-selling-minority-stake-in-citadel">interview</a> with&nbsp;Bloomberg on Thursday at the Economic&nbsp;Club of New York, Griffin stated,&nbsp;"We would be open to&nbsp;the possibility of selling a&nbsp;minority stake in Citadel at&nbsp;some point in the future."
Griffin highlighted the challenges of public capital markets, stating,&nbsp;"We need to make being&nbsp;public in the United States&nbsp;a much more attractive proposition."&nbsp;
Despite the offer, Griffin did not confirm acceptance and ruled out taking Citadel Securities public soon. When considering potential partners, Griffin seeks firms similar to Sequoia that can enhance Citadel&#8217;s business operations.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42102652/michael-saylors-microstrategy-takes-wall-street-by-storm-becomes-second-most-traded-stock-after-nvidia?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Michael Saylor&#8217;s MicroStrategy Takes Wall Street By Storm, Becomes Second-Most Traded Stock After Nvidia</a>
Why It Matters:&nbsp;Griffin, a prominent figure in the financial world, has built&nbsp;Citadel&nbsp;into a powerhouse with over $65 billion in assets. As a mega-donor to the Republican Party, he recently voiced concerns over&nbsp;<a href="https://www.benzinga.com/news/global/24/11/42056528/gop-megadonor-ken-griffin-warns-of-slippery-slope-in-trumps-tariff-policies-sees-us-returning-to-the-business-of-business">Donald Trump&#8216;s tariff policies</a>, warning they could hinder U.S. competitiveness. 
In the past year, Citadel has achieved remarkable financial success, <a href="https://www.benzinga.com/general/23/12/36365068/show-me-the-money-inside-ken-griffins-citadels-jaw-dropping-7-billion-return">returning $7 billion to clients </a>after a 30% profit surge. Citadel&#8217;s multistrategy fund, Wellington, has gained nearly 15% year-to-date, making it one of the top-performing hedge funds. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42102769/floki-beats-dogecoin-shiba-inu-with-double-digit-gains-after-coinbase-listing-announcement?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Floki Beats Dogecoin, Shiba Inu With Double-Digit Gains After Coinbase Listing Announcement</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo by Dan G via Flickr

GOP Megadonor Ken Griffin Is 'Open To The Possibility' Of Selling Minority Stake In Citadel

The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index moved to the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled higher on Thursday, with the Dow Jomes index gaining more than 450 points during the session.
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares rose by 0.5% on Thursday after the company posted upbeat earnings and sales results. Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares fell 2.2% on Thursday following a report suggesting the company is likely to be investigated under the EU&#8217;s Digital Markets Act next year.
Shares of Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) plunged around 4.7% following the U.S. Department of Justice&#8217;s (DOJ) announcement of sweeping remedies in its high-profile antitrust lawsuit against Google.
On the economic data front, U.S. existing home sales gained by 3.5% from the previous month to an annualized rate of 3.96 million in October. The Philadelphia Fed Manufacturing Index fell to -5.5 in November from 10.3 in the previous month, and compared to market estimates of 8. U.S. initial jobless claims declined by 6,000 from the previous week to 213,000 in the week ending Nov. 16.
Most sectors on the S&amp;P 500 closed on a positive note, with utilities, financials, and consumer staples stocks recording the biggest gains on Thursday. However, consumer discretionary and communication services stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 462 points to 43,870.35 on Thursday. The S&amp;P 500 rose 0.53% to 5,948.71, while the Nasdaq Composite rose 0.03% at 18,972.42 during Thursday's session.
Investors are awaiting earnings results from Destination XL Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) and Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 57.4, the index moved to the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 49.6.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42114009/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Long Ideas

Pre-Market Outlook

AMZN

DXLG

GOOG

GOOGL

NVDA

Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To 'Greed' Zone

The gross proceeds to the Company from the offering are expected to be approximately $8.2 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures. The offering is expected to close on or about November 25, 2024, subject to the satisfaction of customary closing conditions.

MODD

Reported Earlier, Modular Medical Prices $8.2M Public Offering Of 5,450,573 Common Shares At $1.50/Share

The Company intends to use the net proceeds from the Offering for general corporate purposes, including funding future investments, making capital expenditures and funding working capital. The Company has granted the underwriters a 30-day option to purchase up to an additional $7.5 million aggregate principal amount of Notes. The Notes will be issued in minimum denominations of $25.00 and integral multiples of $25.00 in excess thereof. The Offering is expected to close on November 27, 2024.

METC

Reported Earlier, Ramaco Resources Prices $50M Senior Unsecured Notes Offering At 8.375% Interest Due 2029

<ul>
<li>&nbsp;Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024&nbsp;</li>
<li>&nbsp;Milestone payment to be made to HUTCHMED from Takeda&nbsp;</li>
<li>Fruquintinib already launched in several regions including the United States, Europe and China&nbsp;</li>
</ul>

Reported Earlier, HUTCHMED Secures Milestone Payment As Takeda Rolls Out FRUZAQLA In Japanese Market

The New 4.625% Notes will bear interest at a rate of 4.625% per year, to be paid semi-annually on June 23 and December 23, commencing on June 23, 2025. The 9.875% Notes will bear interest at a rate of 9.875% per year, to be paid semi-annually on June 23 and December 23, commencing on June 23, 2025.

Reported Earlier, GrafTech Announces Exchange Offers For $500M And $450M Second Lien Notes Due 2029

With U.S. stock futures trading slightly lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Destination XL Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) to report quarterly earnings at 3 cents per share on revenue of $113.46 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Destination XL shares rose 0.8% to $2.60 in after-hours trading.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) reported better-than-expected earnings for its second quarter and raised its outlook for FY24 gross margin. The company reported quarterly earnings of 54 cents per share, which beat the analyst consensus estimate of 40 cents per share. Gap shares jumped 15.7% to $25.50 in the after-hours trading session.</li>
<li>Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) posted stronger-than-expected earnings for its third quarter on Thursday. The company said it sees FY25 earnings of $6.10 to $6.17 per share. Ross Stores shares climbed 7.1% to $153.11 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Intuit Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) reported upbeat results for its first-quarter results, but issued weak forecast for the current quarter. The company reported quarterly earnings of $2.50 per share, which beat the analyst consensus estimate of $2.35 per share. Quarterly revenue came in at $3.28 billion which beat the consensus estimate of $3.14 billion. Intuit shares fell 5% to $644.74 in the after-hours trading session.</li>
<li>Analysts expect Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) to report quarterly earnings at 3 cents per share on revenue of $127.50 million before the opening bell. Global Blue Group shares gained 11.4% to $6.96 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42114009/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields</a></li>
</ul>
Photo courtesy: Gap

INTU

ROST

Gap, Ross Stores And 3 Stocks To Watch Heading Into Friday

Deepwater Asset Management's managing partner Gene Munster has weighed in on the implications of Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google&#8217;s <a href="https://www.benzinga.com/news/24/10/41616230/sundar-pichai-admits-doj-proposals-could-have-unintended-consequences-google-mapping-out-plan-b-in-c">regulatory challenges</a>, including the potential divestment of the Chrome browser.
What Happened: On Thursday, in an interview with CNBC, Munster highlighted the potential impact of a Chrome spin-off on Google&#8217;s search market share.
According to Munster, spinning off Chrome could reduce Google&#8217;s dominant 90% search market share in developed regions to approximately 80%.
This shift could significantly affect Google&#8217;s search growth, which has been averaging 10–14% in recent quarters, potentially dropping to low single digits or even negative in the short term.
He said, &#8220;People love Google, and they will slowly come back,&#8221; but the stock is down about 5% because this gets to the &#8220;core of half their business, which is search.&#8221;&nbsp;
Despite these concerns, he believes the likelihood of a Chrome spinout is low, citing a lack of precedent for such a move.
See Also:&nbsp;<a href="https://www.benzinga.com/media/24/11/42129847/apple-prepares-to-take-on-openais-chatgpt-google-gemini-live-with-llm-siri-in-2025-report">Apple Prepares To Take On OpenAI&#8217;s ChatGPT, Google Gemini &#8216;Live&#8217; With LLM Siri In 2025: Report</a>
Munster also pointed out that Google's search business forms a significant portion of its revenue and is also a critical pillar for its AI initiatives like Gemini. A drop in search market share could weaken Google's ability to compete with rivals such as ChatGPT-parent OpenAI.
He went on to speak about the interconnectedness of regulatory challenges, noting that the DOJ's scrutiny of Google&#8217;s search deal with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) could further damage the company's search business.
Earlier this year, a lawsuit uncovered that <a href="https://www.benzinga.com/24/11/42083150/googles-20b-search-deal-with-apple-faces-collapse-after-antitrust-ruling-what-it-could-means-for-both-tech-giants?itm_source=parsely-api">Apple received a substantial $20 billion</a> in 2022 to set Google as the default search engine on the Safari browser for iPhones.
For investors, the stakes are high. Munster warned that if such worst-case scenarios unfold, Google's stock could drop another 10–15%.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Tough day for Big Tech on the regulatory front. <a href="https://t.co/kPdWS6xD5T">https://t.co/kPdWS6xD5T</a>
&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1859758359341301773?ref_src=twsrc%5Etfw">November 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The DOJ has been actively pursuing measures to dismantle Google&#8217;s search monopoly, demanding <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">Google divest its Chrome browser</a>. This move is part of broader efforts to restore competition in the search market.
The DOJ has also suggested that Google might need to sell its Android operating system if other measures fail.
The impact of these legal actions has been significant, with <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale">Alphabet&#8217;s market value</a> dropping by over $120 billion on Thursday, marking its steepest decline since January.
In response to the DOJ&#8217;s push, Perplexity AI&#8217;s CEO has also speculated about acquiring Chrome, while OpenAI is considering developing its <a href="https://www.benzinga.com/markets/24/11/42130303/chatgpt-parent-openai-considers-building-its-own-web-browser-to-challenge-googles-search-monopoly-following-doj-push-to-break-up-chrome-dominance">own web browser to challenge</a> Google&#8217;s dominance.
Price Action: On Thursday, Alphabet's Class A shares fell 4.74%, closing at $167.63, while Class C shares dropped 4.56%, ending at $169.24. In after-hours trading, Class A shares declined an additional 0.42% to $166.93, and Class C shares decreased 0.38%, closing at $168.59, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">data from Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42053801/alphabets-life-sciences-firm-verily-to-become-a-standalone-entity-disconnect-from-google">Alphabet&#8217;s Life Sciences Firm Verily To Become A Standalone Entity, Disconnect From Google</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Pixabay

Analyst Color

Tech

Media

AAPL

Google's Chrome Battle Goes Beyond The Browser: Gene Munster Outlines Wider Implications Of DOJ Going After The Search Giant

LIFW

Reported Earlier, LifeWallet Secures $2M Pharmaceutical Settlement Amid Broader Efforts To Recover Improper Healthcare Payments And Partner With Government Efficiency Initiatives

American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) is taking aim at &#8220;gate lice&#8221; &#8211; an industry term for passengers who crowd gates before their boarding group is called &#8211; with new technology being rolled out to <a href="https://www.benzinga.com/24/11/42076876/what-could-trumps-new-dot-pick-mean-for-evs-airlines-railroads">more than 100 U.S. airports during the holiday season</a>.
What Happened: The system, which automatically rejects boarding passes from passengers attempting to board ahead of their assigned group, comes as a welcome relief to airline staff who have long struggled with boarding zone violations.
&#8220;We&#8217;ve heard from our customers that the ability to board with their assigned group is important,&#8221; said Julie Rath, Senior Vice President of Airport Operations, Reservations and Service Recovery at American Airlines. &#8220;The initial positive response from customers and team members has exceeded our expectations.&#8221;
The technology triggers an audible alert if passengers try to board early, allowing gate agents to redirect them to wait for their proper boarding group. 
Following successful trials at airports in Albuquerque, Washington D.C., and Tucson, the expansion will include major facilities such as Austin-Bergstrom International Airport and Hartsfield-Jackson Atlanta International Airport.
See Also: <a href="https://www.benzinga.com/news/global/24/11/42130782/amazon-at-risk-of-major-fine-as-eu-investigates-alleged-preference-for-in-house-products-under-digital-markets-act-report">Amazon At Risk Of Major Fine As EU Investigates Alleged Preference For In-House Products Under Digital Markets Act: Report</a>
Why It Matters: Flight attendants and gate staff have long identified premature boarding attempts as a significant source of frustration, leading to the informal &#8220;gate lice&#8221; nickname for chronic offenders. The new system aims to eliminate such disruptions while preserving boarding privileges tied to &#8220;AAdvantage&#8221; status and fare class.
The software platform also provides gate agents with real-time data on boarding group sizes and incoming flight connections, consolidating multiple applications into a single interface. For passengers traveling with companions in earlier boarding groups, agents can override the system with a single click.
American Airlines, which operates thousands of daily flights to more than 350 destinations across 60+ countries, plans to extend the technology to its hub airports in the coming months.
Price Action: American Airlines&#8217; stock closed at $14.20 on Tuesday, down 1.80% for the day. In after-hours trading, the stock edged up 0.21%. Year-to-date, the stock has gained 5.65%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42130859/as-trump-backs-drill-baby-drill-his-doge-co-lead-elon-musk-believes-all-energy-generation-will-be-solar-heres-what-ubs-recommends-after-election-dip">As Trump Backs &#8216;Drill Baby, Drill,&#8217; His DOGE Co-Lead Elon Musk Believes &#8216;All Energy Generation Will Be Solar&#8217; — Here&#8217;s What UBS Recommends After Election Dip</a></li>
</ul>
Image Via Pixabay
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Travel

American Airlines Targets 'Gate Lice' With New Boarding Tech At 100+ Airports This Holiday Season

Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) will release earnings results for the third quarter, before the <a href="https://www.benzinga.com/quote/BBWI/earnings">opening bell on Monday, Nov. 25.</a>
Analysts expect Bath &amp; Body Works to report quarterly earnings at 47 cents per share. That's down from 48 cents per share a year ago. The Columbus, Ohio-based company projects to report quarterly revenue of $1.58 billion, compared to $1.56 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Nov. 8, Bath &amp; Body Works announced the declaration of its regular quarterly dividend of 20 cents per share payable on Dec. 6, to shareholders of record at the close of business on Nov. 22.
Bath &amp; Body Works shares gained 0.8% to close at $30.75 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/BBWI/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating and cut the price target from $35 to $32 on Nov. 6. This analyst has an accuracy rate of 66%.</li>
<li>BMO Capital analyst Simon Siegel reiterated an Outperform rating and lowered the price target from $52 to $50 on Aug. 29. This analyst has an accuracy rate of 75%.</li>
<li>Goldman Sachs analyst Kate McShane maintained a Buy rating and cut the price target from $60 to $49 on Aug. 29. This analyst has an accuracy rate of 69%.</li>
<li>JP Morgan analyst Matthew Boss maintained a Neutral rating and slashed the price target from $42 to $39 on Aug. 29. This analyst has an accuracy rate of 67%.</li>
<li>Raymond James analyst Olivia Tong maintained a Neutral rating and cut the price target from $51 to $42 on Aug. 29. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying BBWI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="550" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22011415/image-238-1024x550.png" alt="" class="wp-image-660295" style="width:678px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22011415/image-238-1024x550.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22011415/image-238-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22011415/image-238-768x413.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22011415/image-238.png 1232w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42114009/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields</a></li>
</ul>

Price Target

Analyst Ratings

BBWI

Bath & Body Works Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk on Thursday tempered down customer expectations of purchasing the company&#8217;s dedicated robotaxi offering &#8211; <a href="https://www.benzinga.com/topic/tesla-cybercab">the Cybercab</a> &#8211; and its humanoid robot called <a href="https://www.benzinga.com/topic/optimus">Optimus</a> for about $30,000 each, saying it would be possible only on the &#8220;long-term.&#8221;
What Happened: Production needs to exceed a million a year before the company can sell the two products for about $30,000, Musk said. 
&#8220;We need to reach >1M/year production volumes, but, long-term, yes,&#8221; he wrote in a post on X, without clarifying if he is hinting towards a collective production volume of a million or a million individually for both the products.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We need to reach &gt;1M/year production volumes, but, long-term, yes <a href="https://t.co/WE39TnhTdf">https://t.co/WE39TnhTdf</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1859656599897506229?ref_src=twsrc%5Etfw">November 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Tall Promises: During Tesla's annual shareholder meeting in June, Musk said that there will be at least&nbsp;<a href="https://www.benzinga.com/news/24/06/39246781/elon-musk-thinks-humanoid-robots-will-one-day-exceed-human-population-from-nvidias-project-gr00t-to" target="_blank" rel="noreferrer noopener">one humanoid robot</a>&nbsp;for every person in the world in the future, implying a total humanoid robot population of at least 10 billion or more, of which the EV company will have a significant share.
Musk then said that he expects to be&nbsp;<a href="https://www.benzinga.com/news/24/03/37950895/elon-musk-says-cost-of-making-an-optimus-is-half-that-of-manufacturing-a-tesla-ev-despite-complexity" target="_blank" rel="noreferrer noopener">able to sell Optimus at a price point below $30,000</a> once it reaches high-volume production.
In July, the CEO said that the EV company would have "genuinely useful" humanoid robots in low production for use within its factories next year. The company will "hopefully" increase production for other customers in 2026, he said.
As for the Cybercab, Tesla unveiled the car with no pedals or steering wheel in October. The vehicle, CEO&nbsp;Elon Musk&nbsp;then said, will enter production "before 2027" and be priced below $30,000.
History Of Underdelivering: Musk is known for providing price points that the company cannot deliver. 
During the Cybertruck&#8217;s unveiling in November 2019, Musk presented tentative pricing for the stainless steel truck. The dual-motor all-wheel-drive (AWD) variant was projected to begin at $49,900 but is now priced at $79,990 in the U.S.
The top-tier tri-motor all-wheel drive was projected to start at $69,900 but is now priced<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36039263/did-tesla-overpromise-and-underdeliver-with-the-cybertruck"> at a whopping $99,990</a>. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42058338/byd-makes-a-million-nevs-in-less-than-2-months" target="_blank" rel="noreferrer noopener">BYD Makes A Million NEVs In Less Than 2 Months After Beating Tesla For The First Time Since 2022 In Quarterly Revenue</a></li>
</ul>
Photo courtesy: Tesla

TSLA

Tesla CEO Elon Musk Tries To Lower Expectations Of $30K Optimus Or Cybercab

Q3 2024 Operating Highlights:
<ul>
<li>Successfully completed funded research phase of the Indivior collaboration with both Indivior and Addex each selecting GABAB PAM drug candidate for further development in SUD and chronic cough, respectively</li>
<li>Completed Q3 2024 with cash and cash equivalents of CHF3.3 million</li>
</ul>

ADXN

Addex Therapeutics Reported Q3 EPS Of CHF(0.02) Up From CHF(0.03), Cash Balance Of CHF3.35M

BBJP

WisdomTree Trust Japan Total Dividend Fund

Reported Earlier, au Jibun Bank Japan Services Purchasing Managers' Index Preliminary For November 50.2 Vs. 49.7 Prior

Reported Earlier, Japan National Core Consumer Price Index (YoY) For October 2.3% Vs. 2.2% Est.; 2.4% Prior

Renewable energy stocks present a buying opportunity despite recent electoral headwinds, according to UBS analysts, while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk continues to <a href="https://www.benzinga.com/news/24/09/41059891/elon-musk-says-because-almost-none-of-you-do-your-math-sums-the-world-is-largely-not-using-the-big-f">advocate solar power&#8217;s future dominance</a>.
What Happened: UBS analysts on Thursday elevated U.S. and EU renewables to their top-ranking stock theme, citing an attractive entry point following steep post-election losses, <a href="https://markets.businessinsider.com/news/stocks/renewable-energy-stocks-election-trump-power-demand-data-centers-ubs-2024-11">reported</a> Business Insider. 
The announcement comes as clean energy shares have tumbled, with companies like Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) and Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) down over 24% since President-elect Donald Trump&#8216;s victory.
&#8220;The environment of an unrelenting power demand shock puts just about every source of power generation in a solid position to capitalize,&#8221; UBS analysts wrote, pointing to surging power needs from artificial intelligence data centers and corporate sustainability goals.
The analysts remain optimistic despite Trump&#8217;s expected scaling back of President Joe Biden-era clean energy initiatives. They argue that companies could &#8220;grandfather&#8221; existing subsidies and that state-level emission goals will sustain industry growth. 
See Also: <a href="https://www.benzinga.com/news/global/24/11/42129914/jim-cramer-doubles-down-on-nvidia-demand-is-accelerating-as-ai-customers-have-no-choice-but-to-buy-its-chips">Jim Cramer Doubles Down On Nvidia: &#8216;Demand Is Accelerating&#8217; As AI Customers &#8216;Have No Choice&#8217; But To Buy Its Chips</a>
This view comes as Trump, <a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently">who has appointed Musk</a> and Vivek Ramaswamy to co-lead his new Department of Government Efficiency named after cryptocurrency Dogecoin, advocates for increased drilling.
Musk, despite his new role in the incoming Trump administration, has historically remained bullish on renewable energy. &#8220;Once you understand Kardashev Scale, it becomes utterly obvious that essentially all energy generation will be solar,&#8221; he posted on X. He noted that a single square mile receives <a href="https://www.benzinga.com/news/24/09/41059891/elon-musk-says-because-almost-none-of-you-do-your-math-sums-the-world-is-largely-not-using-the-big-f">approximately 2.5 gigawatts of solar energy</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Once you understand Kardashev Scale, it becomes utterly obvious that essentially all energy generation will be solar. Also, just do the math on solar on Earth and you soon figure out that a relatively small corner of Texas or New Mexico can easily serve all US electricity.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1839439841337225277?ref_src=twsrc%5Etfw">September 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
UBS recommends several stocks poised for gains, including NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) and Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) in the U.S., along with European players like Iberdrola (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IBDRY#OTC">IBDRY</a>), Siemens Energy (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SMEGF#OTC">SMEGF</a>), and Orsted (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DOGEF#OTC">DOGEF</a>). The analysts cite historical precedent, noting that solar installations grew 50% during Trump&#8217;s previous term.
The renewable sector&#8217;s growth potential is further supported by expanding applications, including Musk&#8217;s recent suggestion that SpaceX&#8217;s Starlink satellite network could integrate <a href="https://www.benzinga.com/news/24/10/41648885/spacex-ceo-elon-musk-agrees-that-starlink-could-combine-hardware-with-solar-panels-and-batteries">solar panels and batteries into its hardware offering</a>.
While Trump&#8217;s &#8220;drill baby, drill&#8221; <a href="https://www.benzinga.com/news/24/09/40703958/trumps-drill-baby-drill-pledge-may-not-deliver-promised-energy-price-cuts-experts-warn">stance has rattled markets</a>, UBS maintains that investor concerns about the sector&#8217;s future may be &#8220;overdone,&#8221; as corporate and state-level commitments to clean energy persist alongside growing power demands from emerging technologies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42127938/bitcoin-analyst-warns-of-4-6-flash-crashes-before-year-end-as-it-inches-closer-to-100k-thats-the-moment-altcoins-shoot-off">Bitcoin Analyst Warns Of &#8216;4-6 Flash Crashes&#8217; Before Year-End As It Inches Closer To $100K: That&#8217;s The Moment Altcoins &#8216;Shoot Off&#8217;</a></li>
</ul>
Photo via Unsplash
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

DOGEF

ENPH

GNRC

IBDRY

PLUG

SMEGF

As Trump Backs 'Drill Baby, Drill,' His DOGE Co-Lead Elon Musk Believes 'All Energy Generation Will Be Solar' — Here's What UBS Recommends After Election Dip

X4 Pharmaceuticals Q3 2024 Earnings Preview

X4 Pharmaceuticals GAAP EPS of -$0.18 misses by $0.01, revenue of $0.56M misses by $1.13M

Reports Q3 revenue $600,000, consensus $1.69M. X4 had $135.8M in cash, cash equivalents, restricted cash, and short-term marketable securities as o...

X4 Pharmaceuticals reports Q3 EPS (18c), consensus (17c)

X4 Pharmaceuticals (XFOR) announced positive new clinical data from its now completed Phase 2 clinical trial evaluating mavorixafor, an oral CXCR4 ...

X4 reports data from Phase 2 clinical trial evaluating mavorixafor

Stifel lowered the firm's price target on X4 Pharmaceuticals (XFOR) to $4 from $5 and keeps a Buy rating on the shares. Sequentially flat Xolremdi ...

X4 Pharmaceuticals price target lowered to $4 from $5 at Stifel

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

X4 Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation

X4 Pharmaceuticals ( ($XFOR) ) has released its Q3 earnings. Here is a breakdown of the information X4 Pharmaceuticals presented to its investors. ...

X4 Pharmaceuticals Reports Positive Trial Results and Progress

H.C. Wainwright lowered the firm's price target on X4 Pharmaceuticals (XFOR) to $1.50 from $5 and keeps a Buy rating on the shares following the Q3...

X4 Pharmaceuticals price target lowered to $1.50 from $5 at H.C. Wainwright

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

AGEN

AXSM

CYCC

HRTX

MCRB

RIGL

SNDX

SWTX

XFORW

Press Releases

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Comments

X4 Pharmaceuticals

X4 Pharmaceuticals (XFOR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga